Cite
MLA Citation
Zev A Wainberg et al.. “Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.” Lancet oncology, vol. 23, no. 11, 2022, pp. 1430–1440. http://access.bl.uk/ark:/81055/vdc_100168599730.0x000014